Back to top
more

Collegium Pharmaceutical (COLL)

(Real Time Quote from BATS)

$35.26 USD

35.26
96,668

+0.12 (0.34%)

Updated Apr 16, 2024 12:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (149 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for COLL

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

1 item in cart

View Cart/Checkout

Collegium Pharmaceutical, Inc. [COLL]

Reports for Purchase

Showing records 1 - 20 ( 91 total )

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 1

02/23/2024

Company Report

Pages: 8

4Q Beat and 2024 Guide Reiterated

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 2

11/21/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for COLL 112123

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 3

08/04/2023

Company Report

Pages: 8

2Q Light Revs, But Reiterated Guidance; Accelerated Stock Repurchase Signals Management Confidence; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 4

05/05/2023

Company Report

Pages: 9

Record 1Q as Expected; We Get the Sense Long-Sought Diversifying Biz Dev is Closer

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 5

02/27/2023

Company Report

Pages: 8

Guidance Achievable Without Rx Growth, But We’d Like to See Revived Volume Trajectory For Longer Term Confidence

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 6

02/09/2023

Company Report

Pages: 8

Strong Preliminary 4Q Results; Opportunistic Favorable Debt Balance Sheet Bolstering

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 7

01/05/2023

Company Report

Pages: 8

First-Time 2023 Guide Beats Estimates, Reflecting Major Xtampza ER Economics Boost

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 8

11/04/2022

Company Report

Pages: 8

Solid 3Q Albeit Upside Boosted by One-Offs; Renegotiated Xtampza Contracts Tee Up 2023 Revenue Jump; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 9

08/08/2022

Company Report

Pages: 11

We See Stock Stuck Until Rx Trends and Xtampza Economics Improve; Can’t Hang Thesis on M&A Alone; Downgrade to Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 10

05/12/2022

Company Report

Pages: 8

1Q22: A Welcome Clean Start to 2022; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 11

04/06/2022

Company Report

Pages: 8

Solid, and Likely Conservative, First-Time 2022 Guide Post BDSI Acquisition

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 12

02/28/2022

Company Report

Pages: 8

Muddled 4Q Ending Challenging Year, But Stand-Alone Guidance Looks Solid; BDSI Deal Close On Tap; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 13

02/15/2022

Company Report

Pages: 6

Collegium Snares Its Commercial, High-Synergy Takeout Target in BDSI; Raise Price Target to $29

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 14

01/21/2022

Company Report

Pages: 5

Risks Abundant with No Guidance

Provider: BWS Financial

Analyst: KHORSAND H

Price: 5.00

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 15

11/05/2021

Company Report

Pages: 9

COVID-Related Mix Shift Worsened in 3Q; All Eyes Now On 2022 Guidance and Execution

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 12.50

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 16

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for COLL

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 17

08/09/2021

Company Report

Pages: 5

The Slow Unwind

Provider: BWS Financial

Analyst: KHORSAND H

Price: 10.00

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 18

08/06/2021

Company Report

Pages: 9

2Q21: Worse Than Expected COVID Impact on Xtampza ER Economics Yields Lower Sales Guidance

Provider: H.C. Wainwright & Co., Inc.

Analyst: LIVNAT O

Price: 25.00

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 19

08/02/2021

Company Report

Pages: 2

Termination of Sell Side Coverage

Provider: G.RESEARCH, LLC

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Collegium Pharmaceutical, Inc.

Industry: Medical - Drugs

Record: 20

07/14/2021

Company Report

Pages: 2

Q2 Rx Recap-Buy

Provider: G.RESEARCH, LLC

Analyst: KEDRA K

Price: 10.00

Research Provided by a Third Party